Email this article Kidney injury associated with monoclonal gammopathies: Perspectives on diagnosis and treatment
- Authors: Kozlovskaya LV1, Rameev VV1, Mrykhin NN1, Kogarko IN1, Kogarko BS1
-
Affiliations:
- Issue: Vol 87, No 6 (2015)
- Pages: 108-111
- Section: Editorial
- URL: https://ter-arkhiv.ru/0040-3660/article/view/31804
- ID: 31804
Cite item
Full Text
Abstract
It is currently well justified that monoclonal gammopathies are the most important predictor for kidney diseases, including glomerulonephritis. To determine a correlation of nephropathy with oligosecretory gammopathy is of fundamental importance, as the treatment of these patients necessitates the use of special chemotherapy regimens to eliminate a pathological clone of lymphocytes or plasmocytes. If this clone is not eliminated, injury of the organ may recur to develop its failure. The principles of this therapy have been presently tried out by the example of AL-amyloidosis and showed its efficiency and relatively low toxicity.
Keywords
References
- Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64:814-826.
- Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ. III Prevalence of Monoclonal Gammopathy of Undetermined Significance. NEJM. 2006;354:1362-1369.
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
- Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood. 2004;103(10): 3960-3963.
- Bradwell AR. Serum free light chain analysis, 4th edition, 2006, The Binding Site Ltd.
- Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S, Quattrocchio G, Rollino C, Segagni S, Locatelli F. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors. Am J Kidney Dis. 2003;42(6):1154-1163.
- Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis — the archetype of structural and pathogenic variability. J Struct Biol. 2000;130(2-3):280-289. Review.
- Abraham RS, Geyer SM, Price-Troska TL, Allmer C, Kyle RA, Gertz MA, Fonseca R. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801-3018.
- Teng J, Russell WJ, Gu X, Cardelli J, Jones ML, Herrera GA Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest. 2004;84(4):440-451.
Supplementary files
